ACTR-04. BIOMARK: A PHASE II STUDY OF BEVACIZUMAB BEYOND PROGRESSION FOR NEWLY DIAGNOSED GLIOBLASTOMA: SAFETY, EFFICACY AND PROSPECTIVE BIOMARKER ANALYSIS

BACKGROUND: Clinical benefit of continuing bevacizumab beyond progression is unknown in glioblastomas. A biomarker analysis of the AVAglio trial suggested that proneural subtype of IDH-wildtype glioblastoma patients may receive an OS benefit from a first-line bevacizumab. This study explored biomark...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Ichimura, Koichi, Nagane, Motoo, Kato, Mamoru, Narita, Yoshitaka, Aoki, Tomokazu, Tanaka, Shota, Mukasa, Akitake, Wakabayashi, Toshihiko, Uzuka, Takeo, Nakamura, Hideo, Arakawa, Yoshiki, Suehiro, Satoshi, Nakada, Mitsutoshi, Kitahara, Mai, Hibiya, Yuko, Narushima, Daichi, Onuki, Ritsuko, Morita, Satoshi, Nishikawa, Ryo
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Adult Clinical Trials - Non-Immunologic
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6846955/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.048
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados